Presentations

Ifabotuzumab (anti-EphA3)

American Society of Hematology (“ASH”) Annual Meeting, December 2014
Title: EphA3 is Expressed on Leukemia Stem Cells, and Eph/ephrin Signalling Features in the Remodelling of the Leukemia Stem Cell Niche.

American Society of Hematology (“ASH”) Annual Meeting, December 2014
Title: KB004, a Novel Non-Fucosylated Humaneered® Antibody, Targeting EphA3, is Active and Well Tolerated in a Phase 1/2 Study of Advanced Hematologic Malignancies

American Society of Hematology (“ASH”) Annual Meeting, December 2013
Title: A Phase I Study of KB004, a Novel Non-fucosylated Humaneered® Antibody, Targeted Against the Receptor Tyrosine Kinase EphA3 in Advanced Hematologic Malignancies

American Society of Hematology (“ASH”) Annual Meeting, December 2010
Title: A Recombinant Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Against Various Hematologic Malignancies Shows Selective Inhibition of Colony Formation From Long-Term Culture-Initiating Cells (LTC-ICs) In Primary Leukemia Samples

American Society of Hematology (“ASH”) Annual Meeting, December 2009
Title: A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity Against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells

Disclaimer: The information contained in the listed publications concerns biologics that are under pre-clinical and/or clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration (FDA). They are currently limited by Federal law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated.